Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Leukemia
Leukemia
Novel Anti-CD20 Antibodies Show Promising Results in Unfit Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Read More
Leukemia
Promising Drugs in the Pipeline for Leukemia and Myelodysplastic Syndromes
Wayne Kuznar
Read More
Leukemia
Initial Choice of TKI in Patients with CML Probably Not Important
Mark Knight
Read More
Leukemia
Evidence Lacking for Eliminating Prophylactic Platelet Transfusions
Audrey Andrews
Read More
Leukemia
Ibrutinib: It’s Not Just for Leukemia
Audrey Andrews
Read More
Leukemia
Molecular and Cytogenetic Assessments Infrequently Performed in Patients with CML Receiving First-Line Imatinib
Mark Knight
Read More
Leukemia
Alternatives to “7 + 3” Induction Therapy for AML Are Emerging
Wayne Kuznar
Read More
Leukemia
Fast Response Identifies Patients with CML for Entry into Studies of Imatinib Discontinuation
Wayne Kuznar
Read More
Leukemia
“Dramatic” Responses with Targeted Agent for Patients with CLL
Charles Bankhead
Read More
Leukemia
New Oral TKI Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
Read More
3
4
5
6
7
Page 6 of 7
Results 51 - 60 of 70